Trials / Completed
CompletedNCT01876511
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 113 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative colon cancer and 3. patients with other MSI positive cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-3475 | MK-3475 10 mg/kg every 14 days |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2013-06-12
- Last updated
- 2020-02-06
- Results posted
- 2020-01-07
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01876511. Inclusion in this directory is not an endorsement.